(NASDAQ: TNYA) Tenaya Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Tenaya Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast TNYA's revenue for 2025 to be $1,313,739,690, with the lowest TNYA revenue forecast at $1,313,739,690, and the highest TNYA revenue forecast at $1,313,739,690. On average, 2 Wall Street analysts forecast TNYA's revenue for 2026 to be $1,532,696,305, with the lowest TNYA revenue forecast at $1,313,739,690, and the highest TNYA revenue forecast at $1,751,652,920.
In 2027, TNYA is forecast to generate $24,904,125,390 in revenue, with the lowest revenue forecast at $4,379,132,300 and the highest revenue forecast at $45,429,118,480.